Benjamin L. Palleiko, CEO of KalVista Pharmaceuticals (NASDAQ:KALV), sold 10,926 shares of common stock on May 22, 2026, at $26.7844 per share, totaling $292,646.
The sale occurred as the stock traded near its 52-week high, following a 134% return over the past year. According to Bond.az analysis, the stock remains undervalued relative to its Fair Value.
The sale was conducted to cover tax withholding obligations from vesting restricted stock units (RSUs). After the transaction, Palleiko directly holds 479,989 shares.
In recent news, KalVista announced a merger agreement to be acquired by Chiesi Group for $27.00 per share, representing a 36% premium.












